Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The user has been using oral finasteride, minoxidil, and biotin for 10 months, noticing some stabilization and thicker baby hairs but not as much progress as expected. They are considering adding topical minoxidil and possibly switching to dutasteride.

PP405 was ineffective for hair growth as some follicles were already active before treatment, raising doubts about its efficacy. Users discussed other hair loss treatments like Minoxidil, finasteride, and RU58841, expressing skepticism and hope for future solutions.

A user shared their 10-week progress using oral finasteride and topical minoxidil for hair loss, reporting significant improvement with no side effects from finasteride and increased body hair from minoxidil. Others in the conversation noted varying results with similar treatments.

PP405 is expected to work for hair regrowth by reactivating stem cells in hair follicles, with FDA approval anticipated in 2027-28. Users express both optimism and skepticism about its effectiveness and the lengthy approval process.

The conversation discusses the effectiveness of 5% versus 10% minoxidil, especially when combined with tretinoin, for hair loss treatment. The user is also using oral minoxidil, derma stamping, and has previously used finasteride, but is unsure of the results.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

Users discussed the effectiveness of Everychem's solution, similar to PP405, with some reporting improved hair thickness and new growth. Concerns were raised about safety and the legitimacy of the product, with some users advising against purchasing research chemicals.

People are discussing the potential of a new hair loss treatment, pp405, and its approval timeline, comparing it to existing treatments like Minoxidil and finasteride. There is skepticism about its effectiveness and concerns about the time it will take for approval and availability, especially in Europe.

A 39-year-old man has been using finasteride for 10 months and minoxidil for 5-6 years with some improvement, considering a hair transplant but unsure whether to wait for more results from finasteride. Users suggest continuing finasteride, possibly adding tretinoin, and considering a hair transplant while maintaining medication.

The conversation discusses skepticism about the effectiveness of PP405 for hair loss, with users mentioning treatments like dutasteride, oral minoxidil, clascoterone, and upcoming drugs like breezula and long-release oral minoxidil. Some users express hope for future treatments like vdphl01 and amplifica, while others debate the effectiveness and side effects of current options.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

The user experienced significant hair regrowth using 1.25mg finasteride daily and 5% topical minoxidil nightly, with no major side effects or shedding. The progress is evident, especially around the temple area, and the user is hopeful for continued growth.

VDPHL01 shows faster and stronger hair growth compared to standard minoxidil, with no major side effects reported. Users discuss combining it with other treatments like dutasteride and finasteride for better results, while expressing skepticism about the effectiveness of PP405.

Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.

An 18-year-old shares progress on hair regrowth after 10 months of oral minoxidil and 5 months of oral finasteride, expressing frustration with hair thinning and hairline issues. Users encourage patience, noting visible growth and progress, while discussing the difficulty of recovering a receded hairline.

PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.

Lactic acid is not effective for hair growth when applied topically. JXL069, finasteride, and minoxidil are suggested as alternative treatments.

A user experienced severe hair shedding and hairline recession after 10 months on finasteride. They are considering switching to dutasteride or adding minoxidil.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

Concerns about the potential high cost of new hair loss treatments, pp405 and gt20029, were discussed, with some users willing to pay a premium if they are effective. Alternatives like finasteride and minoxidil are mentioned as current, more affordable options, and there is speculation about future generic versions and black market availability.

JXL082 is not the same as PP405, leading to a halt in sales and a plan to synthesize the real PP405. There is skepticism about the safety and effectiveness of JXL082 and PP405, with concerns about patent issues and the long-term impact on hair growth.

PP405 is considered as a potential hair regrowth treatment, but users are skeptical due to past product failures. They compare it to Minoxidil and Finasteride, questioning its effectiveness and the intentions of pharmaceutical companies.

A 23-year-old male used 1.25mg finasteride every other day for 10 months without minoxidil, noticing results at the 4-month mark and experiencing a minor shed at the 8-month mark. He also added Nizoral to his routine and reported no side effects, maintaining consistent use at 7:00 PM.

A 20-year-old user experienced worsening hair loss despite using various treatments including topical and oral minoxidil, finasteride, and dutasteride. Other users suggested additional treatments like JAK inhibitors, RU58841, and lifestyle changes, but the user remains skeptical and frustrated.

The user reports progress in hair regrowth using topical finasteride/minoxidil, microneedling, topical dutasteride, latanoprost, and MSM supplements. They express frustration over the lack of interaction on progress posts compared to trivial topics.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

The conversation discusses the lack of updates on GT20029 for hair loss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

A user shared their positive experience and results 10 months after a hair transplant at Mercure Istanbul Clinics, using 3000 grafts. They expressed satisfaction with both the outcome and the clinic's service.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. PP405 is still under evaluation for safety.